Ufp Technologies Inc Revenue Growth Rates (UFPT), Current and Historic Growth - CSIMarket
CSIMarket
 


Ufp Technologies Inc   (NASDAQ: UFPT)
 

UFPT's Revenue Growth by Quarter and Year

Ufp Technologies Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/UFPT/growth
https://api.csimarket.com/api/v1/companies/UFPT/fundamentals
https://api.csimarket.com/api/v1/companies/UFPT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
UFPT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 172.43
2nd Quarter June 173.96
1st Quarter March 153.36
FY 499.75

UFPTs Annual Revenue
Ufp Technologies Inc 's Revenue in the fiscal year 2025 $ 602.41 millions
Ufp Technologies Inc 's Revenue in the fiscal year 2024 $ 503.69 millions
Ufp Technologies Inc 's Revenue in the fiscal year 2023 $ 399.23 millions
Ufp Technologies Inc 's Revenue in the fiscal year 2022 $ 353.79 millions
Ufp Technologies Inc 's Revenue in the fiscal year 2021 $ 206.32 millions




UFPT Revenue third quarter 2026 Y/Y Growth Comment
Ufp Technologies Inc reported Revenue increase of 12.15% year on year in the third quarter 2026, to $ 172.43 millions, this is lower than Ufp Technologies Inc 's recent average Revenue increase of 13.14%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 70 other companies have achieved higher Revenue growth. While Ufp Technologies Inc ' s Revenue growth of 12.15% ranks overall at the positon no. 1289 in the third quarter 2026.




UFPT Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.15 %
2nd Quarter June 15.56 %
1st Quarter March 4.22 %
FY   -

Financial Statements
Ufp Technologies Inc 's third quarter 2026 Revenue $ 172.43 millions UFPT's Income Statement
Ufp Technologies Inc 's third quarter 2025 Revenue $ 153.75 millions Quarterly UFPT's Income Statement


UFPT Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -0.88 %
2nd Quarter June 13.43 %
1st Quarter March 1.58 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #71
Healthcare Sector #228
Overall #1289

Revenue Y/Y Growth Statistics
High Average Low
91.18 % 13.14 % -17.03 %
(Dec 31 2022)   (Mar 31 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #71
Healthcare Sector #228
Overall #1289
Revenue Y/Y Growth Statistics
High Average Low
91.18 % 13.14 % -17.03 %
(Dec 31 2022)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ufp Technologies Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
32.43 % 3.11 % -11.67 %
(Jun 30 2022)  


UFPT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Ufp Technologies Inc disclosed decrease in Revenue from the second quarter by -0.88% to $ 172.43 millions, from $ 173.96 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Ufp Technologies Inc 's Revenue growth quarter on quarter, overall rank is 694.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #31
Healthcare Sector #117
Overall #694
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #31
Healthcare Sector #117
Overall #694
Revenue Q/Q Growth Statistics
High Average Low
32.43 % 3.11 % -11.67 %
(Jun 30 2022)  


UFPT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Ufp Technologies Inc disclosed decrease in Revenue from the second quarter by -0.88% to $ 172.43 millions, from $ 173.96 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Ufp Technologies Inc 's Revenue growth quarter on quarter, overall rank is 694.


Ufp Technologies Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 632.04
Y / Y Revenue Growth (TTM) 7.62 %
Year on Year Revenue Growth Overall Ranking # 475
Seqeuential Revenue Change (TTM) 3.85 %
Seq. Revenue Growth (TTM) Overall Ranking # 1783


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Ufp Technologies Inc 's cumulative twelve months Revenue were $ 632 millions, company would post below average annual Revenue growth of 3.85% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Ufp Technologies Inc 's Revenue growth from the 173.96% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 446 to 475.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 105
Healthcare Sector # 114
Overall # 475

Revenue TTM Y/Y Growth Statistics
High Average Low
71.48 %
12.99 %
-9.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 280
S&P 500 # 1783
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Ufp Technologies Inc 's cumulative twelve months Revenue were $ 632 millions, company would post below average annual Revenue growth of -9.85% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Ufp Technologies Inc 's Revenue growth from the 173.96% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 446 to 475.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 105
Healthcare Sector # 114
Overall # 475

Revenue TTM Y/Y Growth Statistics
High Average Low
71.48 %
12.99 %
-9.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 280
S&P 500 # 1783




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
UFPT's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Harvard Apparatus Regenerative Technology Inc 17.89%$ 17.886 millions
Outset Medical Inc 17.51%$ 17.510 millions
Cv Sciences Inc 17.41%$ 17.410 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions


About Ufp Technologies Inc Revenue Growth Rates (UFPT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ufp Technologies Inc (CIK 914156).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-071504
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ufp Technologies Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.